




evogene
REAL-WORLD INNOVATION



REAL-WORLD INNOVATION

AI-first driven discovery platform for multi-parameter small-molecule generation

July 29, 2026

FORWARD LOOKING STATEMENT

This presentation contains "forward-looking statements" relating to future events, and Evogene Ltd. (the "Company"), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered "forward-looking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA") and other securities laws, as amended. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Such forward-looking statements may be identified by the use of such words as "believe", "expect", "anticipate", "should", "planned", "estimated", "intend" and "potential" or words of similar meaning. We are using forward-looking statements in this presentation when we discuss our value drivers, commercialization efforts and timing, product development and launches, estimated market sizes and milestones, pipeline, as well as our capabilities and technology.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this presentation. Therefore, actual future results, performance or achievements, and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control, including, without limitation, the current war between Israel and Hamas and any further adverse impact that it may have on economic activity in Israel due to the calling up of a large number of reserve soldiers or the incurrence of debt to pay for the high cost of the war, and any accompanying future uncertainties for the security of the Company's operations in southern Israel, as well as those additional factors described in greater detail in Evogene's Annual Report on Form 20-F and in other reports Evogene files with and furnishes to the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading "Risk Factors".

Except as required by applicable securities laws, we disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of the Company, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract or commitment relating thereto or to the securities of the Company.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services.

EVOGENE PIONEERS **REAL-WORLD INNOVATION**

Using a proprietary generative AI engine, we generate novel and highly potent small molecules, optimized across multiple-parameters, for the pharmaceutical and ag-chemical industries



OUR STORY

PIONEERING IN PHARMA

Growing number of collaborations for a diverse pipeline of drug candidates



GEN AI ENGINE

ChemPass AI™ – computational engine for the generation & optimization of small molecules




REVOLUTIONIZING AG

Proven strategic collaborations driving our ag-chem pipeline



THE DISCOVERY & OPTIMIZATION CHALLENGE

GENERATE THE RIGHT CANDIDATES TO REACH THE MARKET



DIVERSE NOVEL CHEMICAL STRUCTURES & MULTI-PARAMETER **CHALLENGE**

The challenge - generate **diverse** small molecules with **novel** chemical structures that satisfy all **required parameters** defining the desired product, while proactively balancing multiple, often competing, criteria

CURRENT MAIN LIMITATIONS:

- Confined to a limited chemical space
- Lacks capability to perform multi-parameter optimization simultaneously



CHEMPASS AI™

BREAKING CHEMICAL SPACE LIMITATION & MULTI-PARAMETER CHALLENGE



NOVEL CHEMICAL STRUCTURE - DRUG-LIKE, SYNTHESIZABLE MOLECULES

Our AI engine generates novel compounds that are synthesizable and active, while accessing unexplored chemical space and creating new IP opportunities

MULTI-PARAMETER OPTIMIZATION

Multiple-parameters optimized to project-specific chemical, biological, and physical constraints, increasing probability of success

CHEMOTYPE DIVERSITY - DE-RISKING DOWNSTREAM DEVELOPMENT

A broad and diverse scope of development candidates, that meet the defined product specifications

CHEMPASS AI™ - THREE STEPS TO SUCCESS

Step 1


HIT SCREENING WITH POINTHIT™

Utilizing deep learning to enhance rapid screening of ultra-large databases

VIRTUAL SCREEN RESULTS

POINTHIT

TRADITIONAL METHOD



Step 2

HIT TO LEAD WITH ACTIVESEARCH™

DMTA* coupled with upgraded analog search using proprietary algorithms

ACTIVSEARCH RESULTS

1,800

SELECTED & PURCHASED

41

ACTIVE

16

SUB MICROMOLAR POTENCY


7

UP TO 400-FOLD IMPROVEMENT

Step 3

LEAD OPTIMIZATION WITH LEADOP GPT™


Simultaneous optimization of multiple parameters using generative AI



REACHED MULTI-PARAMETER OPTIMIZED
nMol ACTIVE NOVEL COMPOUNDS

Result

EVOGENE PRODUCT CANDIDATE



EVOGENE'S UNIQUE OFFERING – NOVEL CHEMISTRY THAT WORKS

***POINTHIT™ & ACTIVESEARCH™* - INTELLIGENCE: UNIQUE DATASET CREATION**


- Both *POINTHIT™* & *ACTIVESEARCH™* explore ultra-large vendor libraries ~ **70B molecules**
- *POINTHIT™* utilizes virtual screening to generate a diverse range of chemotypes from the earliest stages of the discovery process
- *ACTIVESEARCH™* is an analogue search-engine coupled with QSAR to optimize DMTA cycles



Deep understanding of the biology and chemistry underlying the target product

***LEADOP GPT™* - THE MAGIC: NOVEL MOLECULE GENERATION**

- In-house built AI engine trained on curated **38B molecules database** ([Google Cloud collaboration #1](#))
- Generation of molecules that satisfy multiple project-specific parameters simultaneously ([Google Cloud collaboration #2](#))
- Precision generation of novel bioactive molecules tailored to target product criteria, eliminating inefficient traditional filtering



TECHNOLOGICAL COLLABORATIONS WITH GOOGLE CLOUD

FROM GENERATIVE MODELS TO AUTONOMOUS DISCOVERY



FIRST COLLABORATION – FIRST-IN-CLASS FOUNDATION MODEL

Successful completion of a proprietary generative AI model for novel molecular product candidates addressing multiple parameters, based on **38 billion** molecular structures, delivered **90% precision** compared to approx. 30% in traditional GPT models*.

SECOND COLLABORATION – ADVANCED AI AGENTS INTEGRATION


Integration of AI agents into ChemPass AI™ using Google Cloud Agent Platform to produce data for multi-parameter modeling, accelerate design-make-test-analyze cycles, and scale the discovery of patentable small molecules with stronger potential for commercial success across pharmaceutical and agricultural pipelines. Initiated Feb. 2026



"This expanded collaboration with Evogene demonstrates the power of integrating cutting-edge artificial intelligence into scientific research. By leveraging our technology to deploy advanced AI agents, we are enabling Evogene to automate and scale their complex discovery workflows. This foundation accelerates the speed and precision of identifying small molecules, further cementing Evogene's role as a leader in next-generation molecular design for the pharmaceutical and agricultural industries"

BOAZ MAOZ, MANAGING DIRECTOR, GOOGLE CLOUD ISRAEL (10.02.2026)

CHEMPASS AI™ - GENERATES CANDIDATES FOR COMMERCIAL SUCCESS




BUSINESS STRATEGY

CO-DEVELOPMENT - CAPTURE THE VALUE OF *CHEMPASS AI™*


Unlock the full potential of ChemPass AI™ through strategic collaborative partnerships, accelerating innovation in small-molecule drug and agrochemical development

PARTNERING WITH PHARMA, AG-CHEMICAL & BIOTECH COMPANIES that complement our capabilities, enabling groundbreaking innovations that benefit both parties



MAXIMUM POTENTIAL, MINIMUM RISK

CHEMPASS AI™ WORKFLOW



HARNESSING THE POWER OF CHEMPASS AI FOR REAL-WORLD INNOVATION

PHARMA DIVISION – Drugs



AG DIVISION* – Ag-Chemicals

EXTERNAL COLLABORATIONS



Neutrophil-Derived
Inflammatory Diseases



Demyelination Disorders



Cardiovascular Diseases



Therapy Resistant
Lung Cancer



Metabolic Disease



EXTERNAL COLLABORATIONS



Herbicides

INTERNAL PIPELINE

Wheat Blotch

OUR STORY

PIONEERING IN PHARMA

Growing number of collaborations for a diverse pipeline of drug candidates



GEN AI ENGINE

ChemPass AI™ – computational engine for the generation & optimization of small molecules





REVOLUTIONIZING AG

Proven strategic collaborations driving our ag-chem pipeline



GROWING OPPORTUNITY IN AI-DRUG DISCOVERY




**SMALL
MOLECULES**

Account for
58%¹
of total pharmaceutical market (\$1,344B)

AI-based candidates in pipeline
>60²
150% CAGR in last 3 years

Discovery market expected to reach
~\$190B³
by 2034



AI-FIRST COMPOUNDS UNDER DEVELOPMENT


The indicated data are for March 2025 *

Data includes both in-house and partner programs, data is NOT exhaustive, it reflects only information disclosed by companies on their websites.

 <https://www.biopharmatrend.com/>

 <https://www.TechLifeSci.com>

 @BiopharmaTrend



POTENTIAL COLLABORATORS & BUSINESS DEVELOPMENT STRATEGY

POTENTIAL PARTNERS	UNMET NEEDS	COMMON COLLABORATION PROFILE	TIMELINE
ACADEMIA/ SMALL BIOTECH	1. Rapid computational generation of molecules with high probability of success for novel targets 2. Composition of matter patents	A strategic partnership to co-develop a novel drug asset, generate shared IP and/or commercialization rights while accelerating the path to clinical development	Initiated end of 2025
MID-BIG SIZE BIOTECH/ MID SIZE PHARMA	1. Rapid computational generation of molecules with high probability of success for novel targets 2. Computational generation of novel chemotypes with improved patent positions and introduction of broad chemical diversity	Joint discovery and optimization of novel drug assets. Evogene will receive R&D and milestone-based payments, and royalties	Mid term (2027+)
GLOBAL PHARMA	1. Generation of novel chemotypes with improved patent positions and introduction of broad chemical diversity 2. Computational solutions for non-trivial targets	1. Joint discovery and optimization of novel drug assets. Evogene will receive R&D and milestone-based payments, and royalties 2. Evogene delivers a dedicated computational technology solution for a specific R&D challenge in exchange for upfront, R&D and milestone-based payments	Long term (2028+)

DIVERSIFIED DRUG DISCOVERY PIPELINE – (INITIATED Q4/25)


INDICATION	PROGRAM	HIT ID	HIT-TO-LEAD	LEAD OPTIMIZATION	PRE-CLINICAL	IND	PARTNER
COLLABORATIONS							
Oncology	EVG-O311						Undisclosed
Metabolism*	EVG-M410						
Immunology	EVG-I110						
Neurology	EVG-N210						
Oncology	EVG-O310						
Cardiology	EVG-C610						
INTERNAL PIPELINE							
Undisclosed	EVG-R510						

* Non-protein target

COLLABORATION WITH A LEADING ACADEMIC INSTITUTE (UNDISCLOSED)

NOVEL THERAPIES FOR BREAST CANCER TREATMENT AND LONGEVITY

- Target: novel key mechanism linked to cancer cell survival, migration and therapy resistance
- Global breast cancer therapy market is estimated at \$30-37B annually, with aggressive forms representing 10-15% of the cases, with an estimated market of \$ 1-5B
- Combines *ChemPass AI™* with expertise in spatial genomics and genome stability
- Designed to generate novel small-molecule candidates for aggressive form of breast cancer





BINDING SITE AND LIGAND OF TARGET

POINTHIT™ - SUPERIOR HIT RATES OF HIGHLY POTENT MOLECULES

42 molecules identified with outstanding results*

- 43% of tested considered candidate inhibitors
- 19% of tested compounds have nM efficacy

"We used to screen thousands of compounds to get hits, with ChemPass AI this is not required. Out of 42 compounds, 18 (43%) are inhibitors, and 8 (19%) are potential candidates." PI




* Intermediate analysis

COLLABORATION WITH PROF. EHUD GAZIT, TAU, TEL-AVIV, ISRAEL

NOVEL THERAPEUTIC MODALITY FOR METABOLIC DISEASES



- Target: molecular self-assembly metabolites that underlie metabolic conditions
- Addressable Gout therapeutics market is evaluated at ~\$3B*
- Combines ChemPass AI™ with unique biological research in molecular self-assembly biology
- Creates opportunities for novel therapeutics addressing the cause of disease rather than symptomatic treatment




SCANNING ELECTRON MICROSCOPY OF CRYSTALS
FORMED BY THE SELF-ASSEMBLY OF A METABOLITE

* Costa-Bauza, A., & Grases, F. (2023). Biomolecules, 13(12), 1769.

"We are excited to join forces with Evogene in this groundbreaking endeavor. By integrating our fundamental understanding of molecular self-assembly with Evogene's cutting-edge AI-driven drug design platform, we have a unique opportunity to develop novel therapeutics that specifically target these pathological processes and ultimately improve treatment for patients."

COLLABORATION WITH PROF. EHUD GAZIT, TAU, TEL-AVIV, ISRAEL

NOVEL THERAPEUTIC MODALITY FOR METABOLIC DISEASES – *CHEMPASS AI™* RESULTS



INTERMEDIATE ANALYSIS OF INITIAL 15 MOLECULES

- 33% of tested compounds reach activity threshold
- 2 molecules outperformed positive control

NEXT STEP

- Ongoing testing of additional molecules for hit identification

OUR STORY

PIONEERING IN PHARMA

Growing number of collaborations for diverse drug targets



GEN AI ENGINE

ChemPass AI™ – computational engine for the generation & optimization of small molecules



REVOLUTIONIZING AG

Proven strategic collaborations driving our ag-chem pipeline



~\$88B GROWING MARKET WITH PLENTY OF ROOM FOR INNOVATION

UNMET NEEDS

- 1** Increase of pest resistance
& regulatory requirements
- 2** Urgent need for new
Modes of Action (MoAs)
- 3** Decreased rate in discovery
of new pesticides due to lack
of innovation



\$43.3B
BROAD SPECTRUM
HERBICIDES¹

\$22.2B
FUNGICIDES FOR
MAJOR DISEASES²

\$22.3B
BROAD SPECTRUM
INSECTICIDES³

LEADING CROP PROTECTION COMPANIES

 **BASF**



The FMC logo consists of a red stylized "F" icon followed by the letters "FMC" in bold red capital letters.

The Syngenta logo features the word "syngenta" in blue lowercase letters, with a green leaf icon above the "y".



The Gowan logo features the word "Gowan" in blue capital letters, with a green triangle icon below the "a".

The Nufarm logo features a green stylized leaf icon above the word "nufarm" in green lowercase letters.



The Kureha logo features the word "KUREHA" in blue capital letters, with a green arrow pointing to the right below it.



POTENTIAL DISCOVERY AND OUTLICENSE PARTNERS

CURRENT CROP PROTECTION PIPELINE


PROGRAM	INDICATION	HIT ID	HIT-TO-LEAD	LEAD OPTIMIZATION	SAFETY AND ENVIRONMENTAL	FIELD TESTING	PARTNER
COLLABORATIONS							
Herbicide	APCO-12			Stage confidential			
INTERNAL PIPELINE							
Fungicide	APTF1/APTF4						

INTERNAL PIPELINE WHEAT BLOTCH

DISRUPTING A \$1.2B PROBLEM AT RECORD SPEED


- 70% of EU fungicide usage in wheat is for Wheat Blotch
- EU market alone >\$1.2B annually
- Widespread resistance to current top products ('Strobilurins') with 2025 sales of \$4.76B¹

APTF-1 PRESENTS STRONG POTENTIAL FOR REAL-WORLD INNOVATION



- Shows clear concentration-dependent antifungal efficacy
- Ongoing optimization to enhance potency
- 18 months from target to optimized hit

END-TO-END PROCESS – NOVEL, HIGHLY POTENT, OPTIMIZED MOLECULES



EVOGENE – LOOKING FORWARD

PHARMA DIVISION – DRUGS

- Progress in existing pipeline
- New collaborations with biotech companies and academic institutions
- Building relationships with pharmaceutical companies
- Evaluation of projects for an internal pipeline



AG DIVISION* – AG-CHEMICALS

- Progress in existing pipeline
- New collaborations with ag-chem companies
- Evaluation of projects for expanding internal pipeline



ADDITIONAL TECH COLLABORATIONS TO MAINTAIN OUR COMPETITIVE ADVANTAGE

**NOVEL, DRUG-LIKE,
SYNTHESIZABLE MOLECULES**

**MULTI-PARAMETER
OPTIMIZATION**

**DE-RISKING DOWNSTREAM
DEVELOPMENT**

We generate highly potent and novel small molecules, optimized across multiple-parameters, for the pharmaceutical and ag-chemical industries

ev^ogene
Real-world innovation



PIONEERING IN PHARMA

Growing number of collaborations addressing diverse drug targets for the benefit of human health



REVOLUTIONIZING AG

Proven impact in Agriculture. Computational chemistry drives real-world agricultural impact

**GENERATING REAL-WORLD
INNOVATION**

evogene



Creating

**REAL-WORLD
INNOVATION**

for a better future